Thymalin and Thymosin Alpha-1 are both described as thymic peptides, and they are often compared as if they were two versions of the same thing. They are not. Thymalin is an extract: a mixture of many peptides isolated from calf thymus tissue. Thymosin Alpha-1 is a single, fully defined molecule of 28 amino acids, made by chemical synthesis for its pharmaceutical form.
That difference shapes everything else, including what can be studied, how results can be reproduced, and how far any finding can be carried from one compound to another. It also matters for the third peptide in this comparison. Epithalon, the synthetic tetrapeptide most often mentioned alongside Thymalin, is frequently credited with human longevity data that was actually generated with Epithalamin, a pineal gland extract.
The argument of this post is that the three compounds belong to different evidence categories and should not be blended. The sections below compare Thymalin and Thymosin Alpha-1, set out what is known about Epithalon and its parent extract, review the biology of the thymus–pineal axis, and examine the one human study behind most combination claims.
Two Thymic Peptides That Are Not the Same Kind of Thing
| Thymalin | Thymosin Alpha-1 (Tα1) | |
|---|---|---|
| Form | Polypeptide complex extracted from calf thymus | Single defined peptide, 28 amino acids, N-terminally acetylated |
| Composition | Mixture; identified components include short peptides such as EW, KE and EDP | One sequence; molecular weight about 3,108 Da |
| Origin | Developed in Leningrad (St. Petersburg) in the early 1980s by Morozov and Khavinson | Isolated from thymic tissue by Goldstein’s group in the 1970s; naturally cleaved from prothymosin alpha |
| Best-studied mechanisms | Proposed regulation of T-cell differentiation and gene expression, largely from the developers’ laboratory | Dendritic cell activation through Toll-like receptor signaling; T-cell and cytokine modulation |
| Regulatory status | Used clinically in Russia, according to its developers | Marketed as thymalfasin (Zadaxin) in more than 30 countries; not FDA- or EMA-approved |
| Evidence base | Predominantly one research network, much of it in Russian-language journals | International randomized trials, concentrated in hepatitis B and in Asia |
Thymosin Alpha-1 is also unrelated to thymosin beta-4, despite the shared name. The beta-4 family, and the identity confusion around its fragment TB-500, is covered in our review of what the FDA’s briefing documents found on TB-500 and thymosin beta-4.
Thymalin: A Thymus Extract
Thymalin was the first preparation produced by a technology for isolating polypeptide complexes from young animal organs, developed by Vladimir Morozov and Vladimir Khavinson in the early 1980s (Khavinson et al., Biology Bulletin Reviews, 2021). Its developers describe it as a polypeptide complex from calf thymus used for conditions associated with immune dysfunction.
Because it is an extract, its composition is not defined by a single sequence. Later analytical work by the same group used liquid chromatography–mass spectrometry to identify short peptides within it, including the dipeptide EW, subsequently synthesized as thymogen, and the dipeptide KE and tripeptide EDP (Zhurkovich et al., 2020). The authors propose that these minor components account for much of its biological activity.
That proposal is plausible but not established. It comes from the developers’ own laboratory, and the composition of an extract can vary with source tissue and processing, which makes results harder to reproduce than with a defined molecule.
Thymosin Alpha-1: A Defined 28-Amino-Acid Peptide
Thymosin Alpha-1 was the first peptide isolated from the alpha region of thymic tissue extracts and is characterized as an N-terminally acetylated acidic peptide of 28 amino acids, with a molecular weight of 3,108 Da (Costantini et al., Frontiers in Immunology, 2019). In the body it is produced by cleavage of a larger precursor, prothymosin alpha.
Its mechanisms have been studied in detail outside its country of origin. Work led by Luigina Romani’s group at the University of Perugia showed that Tα1 primes dendritic cells through Toll-like receptor signaling, including TLR9-dependent pathways, and can induce the tolerance-associated enzyme IDO, linking it to both immune activation and immune regulation (Romani et al., 2007).
Regulatory status. The synthetic form, thymalfasin, is marketed as Zadaxin. Its manufacturer, SciClone, reported in its SEC filings that it is approved in over 30 countries, with indications that vary by country and include hepatitis B, hepatitis C, use as a vaccine adjuvant and certain cancers (SciClone 10-K). It is not approved by the U.S. FDA or the European Medicines Agency for general use.
Clinical evidence. Randomized trials exist, most of them in chronic hepatitis B and most conducted in Asia. Results elsewhere are mixed. The largest double-blind trial to date, the TESTS trial in 1,106 adults with sepsis across 22 Chinese centres, found 28-day mortality of 23.4% with Tα1 versus 24.1% with placebo, with no significant difference (Wu et al., BMJ, 2025). Smaller earlier studies had suggested benefit; the larger trial did not confirm it.
How the Evidence Bases Differ
The four compounds discussed in this post sit at very different points on the evidence spectrum.
| Compound | Most-cited human evidence | Design | Independent replication |
|---|---|---|---|
| Thymosin Alpha-1 | Hepatitis B RCTs; TESTS sepsis RCT (negative) | Randomized, some double-blind | Yes, across multiple countries |
| Thymalin | Khavinson–Morozov elderly cohort | Non-randomized, non-blinded | No |
| Epithalamin (pineal extract) | Same cohort; Korkushko et al. trials in elderly patients | Non-randomized cohort; some randomized work by the same network | No independent group |
| Epithalon (synthetic AEDG) | None in humans | Cell culture and animal studies | Partial: one independent cell study (2025) |
The contrast is not that one body of work is Russian and another Western. It is that one compound has been tested by several independent groups in randomized designs, and the others rest largely on a single research network whose key human studies lacked randomization and blinding.
Epithalon and Epithalamin: Keep Them Apart
Epithalamin is a polypeptide extract from bovine pineal gland, developed within the same research program as Thymalin. Epithalon (also spelled Epitalon) is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, designed from the amino acid composition of Epithalamin; the AEDG sequence was later reported as a component of the pineal extract itself. The two are related, but they are not the same substance, and evidence for one does not transfer to the other.
Telomerase. The best-known Epithalon finding is from cell culture. Khavinson and colleagues reported in 2003 that adding the peptide to telomerase-negative human fetal fibroblasts induced expression of the telomerase catalytic subunit, telomerase activity and telomere elongation (Khavinson et al., Bull Exp Biol Med, 2003). An independent 2025 study at Brunel University London reported dose-dependent telomere extension in normal human epithelial and fibroblast cell lines through telomerase upregulation, while in breast cancer cell lines telomere lengthening occurred through the alternative lengthening of telomeres (ALT) pathway (Al-dulaimi et al., Biogerontology, 2025). That second observation is a reason for caution, not reassurance. Neither study measured anything in a living human.
Melatonin. Khavinson-group studies report that pineal peptides normalize melatonin secretion rhythms in aged monkeys and elderly people. These findings come from the same research network and have not been independently replicated.
The practical point is simple. Statements that “Epithalon reduced human mortality” misattribute data. The human cohort used Epithalamin.
The Thymus–Pineal Axis
The idea of linking thymic and pineal peptides rests on real biology. Both glands undergo involution with age, and a substantial literature describes interaction between them. A 2020 review in the International Journal of Molecular Sciences summarizes evidence that the thymus and pineal gland act as a functional unit in immune regulation, notes that pineal removal in mice has been associated with thymic destruction and immune impairment, and highlights melatonin’s immunological roles (Rezzani et al., 2020).
The same review is candid about the limits, describing the available results on thymic and pineal factors other than melatonin as often unclear. A Russian-language review from the Khavinson network argues that pineal peptides had a stronger effect on thymic involution than thymic peptides had on the pineal gland (Linkova et al., Adv Gerontol, 2010), but that conclusion draws largely on animal work from the same group.
The axis is a legitimate research question. It is not, on current evidence, a demonstrated basis for restoring an aged thymus with any particular peptide.
Why Thymalin and Epithalamin Were Studied Together
The combination rationale follows from the axis: if thymic and pineal decline are linked, treating both might matter more than treating either. The main human test of that idea is a single cohort.
Khavinson and Morozov followed 266 people over 60 at the St. Petersburg Institute of Bioregulation and Gerontology for six to eight years, giving Thymalin, Epithalamin or both during the first two to three years (Khavinson & Morozov, Neuro Endocrinol Lett, 2003). They reported mortality 2.0–2.1-fold lower with Thymalin, 1.6–1.8-fold lower with Epithalamin and 2.5-fold lower with both, compared with controls. A separate subgroup given both extracts annually for six years showed a 4.1-fold lower mortality rate.
Those figures are often quoted without their context.
- Design. Controls were not randomized and treatment was not blinded, so differences in who received treatment could explain some or all of the effect.
- Source. The study comes from the developers’ own institute and has not been replicated by an independent group.
- The 4.1-fold figure belongs to a separate, smaller subgroup, not to the main comparison.
- Compounds. The study used Epithalamin, not Epithalon, and did not include Thymosin Alpha-1.
No study combining Thymosin Alpha-1 with Thymalin or Epithalon was identified. Claims of synergy among all three have no direct experimental support. The broader bioregulator framework these compounds come from is discussed in our post on Khavinson peptide bioregulators.
Frequently Asked Questions
Q1: What is the difference between Thymalin and Thymosin Alpha-1?
Direct Answer: Thymalin is a polypeptide extract from calf thymus containing many peptides, while Thymosin Alpha-1 is a single, fully defined 28-amino-acid peptide produced synthetically as thymalfasin.
- Composition: A mixture versus one sequence.
- Evidence: Mostly one research network versus international randomized trials.
- Status: Used clinically in Russia versus marketed in more than 30 countries, but not FDA- or EMA-approved.
Q2: Is Thymosin Alpha-1 approved?
Direct Answer: Thymalfasin is approved in more than 30 countries for indications that vary by country, mainly viral hepatitis, but it is not approved by the U.S. FDA or the European Medicines Agency for general use.
- Manufacturer figure: SciClone’s filings state “over 30 countries”; the frequently quoted “35+” figure appears in secondary sources.
- Indications: Include hepatitis B and C, vaccine adjuvant use and certain cancers, depending on country.
- Sepsis: The largest trial found no mortality benefit.
Q3: Did Thymalin and Epithalon reduce mortality in humans?
Direct Answer: The human mortality data came from Thymalin and Epithalamin, a pineal extract, not Epithalon. One non-randomized, non-blinded cohort from the developers’ institute reported lower mortality, and it has not been independently replicated.
- Cohort: 266 people over 60, followed six to eight years.
- Reported effect: 2.5-fold lower mortality with both extracts; 4.1-fold in a separate subgroup.
- Limits: No randomization or blinding; single research group.
Q4: Does Epithalon activate telomerase in humans?
Direct Answer: This has not been shown. Telomerase activation and telomere elongation have been reported only in cultured cells, including an independent 2025 study, and no human telomere trial has been published.
- 2003: Telomerase induction in human fetal fibroblasts.
- 2025: Telomere extension in normal cell lines; ALT activation in cancer cell lines.
- Gap: Cell culture does not predict effects in living tissue.
Q5: Is there evidence of synergy between Thymalin, Thymosin Alpha-1 and Epithalon?
Direct Answer: No direct evidence was found. The only combination data involve Thymalin with Epithalamin, from a single cohort; no study of Thymosin Alpha-1 combined with either compound was identified.
- Thymalin + Epithalamin: One non-randomized human cohort.
- Thymalin + Epithalon: No human studies identified.
- Tα1 combinations: None identified with these compounds.
Q6: What is the thymus–pineal axis?
Direct Answer: It describes interactions between the thymus and pineal gland in immune and neuroendocrine regulation, including their parallel decline with age. The concept is supported by animal and mechanistic research, but many details remain unclear.
- Shared involution: Both glands decline with age.
- Melatonin: Has documented immunological roles.
- Limits: Evidence on peptide factors other than melatonin is described as inconsistent.
What the Evidence Supports
Thymalin and Thymosin Alpha-1 share an organ of origin and little else. One is a mixture whose active components are still being characterized; the other is a defined molecule with a documented mechanism, international trials, and a mixed record that includes a large negative study. Epithalon and Epithalamin share a name and a research program, but the human data belongs to the extract and the telomere data to the synthetic peptide, in cell culture.
The thymus–pineal axis remains a legitimate and interesting research question. What it does not yet provide is evidence that any of these peptides, alone or combined, restores immune function or extends human life. The single cohort behind most such claims is a starting point for investigation, not a conclusion, and research built on these compounds is better served by keeping their evidence bases separate than by merging them.
Ready to Advance Your Research?
Browse our catalog of verified research peptides, sourced and shipped exclusively within Canada. COAs available on request.
Disclaimer: All Peptide Wave products are intended strictly for laboratory research use only. Not approved for, nor intended for, human or veterinary consumption.
